A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies

Trial Profile

A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
  • Focus Adverse reactions; Biomarker
  • Acronyms Study-003
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 11 Aug 2017 Results of CA209003, CA209037 and CA209066 studies, published in the Journal of Clinical Pharmacology.
    • 10 Jun 2017 Biomarkers information updated
    • 09 Jun 2017 Planned End Date changed from 1 Nov 2016 to 15 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top